Research
Hormonal
Tesofensine (combined with metoprolol) significantly reduces body weight, waist circumference, and glucose levels in adults with hypothalamic obesity compared to placebo.
Tesofensine combined with metoprolol significantly reduces weight, waist circumference, and glucose in adults with hypothalamic obesity. It works by increasing sympathetic tone. Side effects are generally mild.
ModerateSupportsMEDIUM confidence
Tesomet treatment resulted in significant reductions in body weight, waist circumference and glucose levels compared to placebo (92), which were the main efficacy endpoints.
Why this rating
Based on a Phase 2 randomized, double-blind, placebo-controlled trial (n=21 randomized, 18 completed).
Source
Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon
Christian L. Roth et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1256514
narrative_reviewCited 20×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (specifically exenatide) reduce body fat and waist circumference in patients with hypothalamic obesity, with greater adiposity reduction observed in those with more extensive hypothalamic damage.Moderate
- Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, reduces hunger and BMI in patients with hypothalamic obesity caused by acquired hypothalamic injury, marking a potential breakthrough for this condition.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →